Venaxis to Provide Third Quarter 2013 Business Update

            Venaxis to Provide Third Quarter 2013 Business Update

Conference Call and Webcast scheduled for November 7, 2013, 8:30 a.m. ET

PR Newswire

CASTLE ROCK, Colo., Oct. 31, 2013

CASTLE ROCK, Colo., Oct. 31, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance for
and commercializing its CE Marked APPY1™ Test, a rapid, multiple
biomarker-based assay for identifying patients that are at low risk for
appendicitis, today announced it will provide a third quarter business update
on Thursday, November 7, 2013, at 8:30 a.m. ET. The conference call will be
hosted by Steve Lundy, Chief Executive Officer; Jeff McGonegal, Chief
Financial Officer; and Don Hurd, Senior Vice President and Chief Commercial
Officer.

Interested participants and investors may access the conference call by
dialing 1 (877) 870-4263 (U.S.), 1 (855) 669-9657 (Canada) or 1 (412) 317-0790
(international). A live audio webcast will be accessible via the Investor
Relations section of the Venaxis™ web site, ir.venaxis.com.

A telephonic replay of the call will be available for 90 days beginning
approximately on hour after the end of the conference call through February 7,
2014. Access numbers for this replay are 1 (877) 344-7529 (U.S./Canada) and 1
(412) 317-0088 (international); conference ID: 10036520. The webcast replay
will remain available in the Investors Relations section of the Venaxis web
site for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric, adolescent and
young adult patients with abdominal pain, as this population is at the highest
risk for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, an initial
launch for the APPY1 Test is ongoing in select European countries. For more
information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for the APPY1 Test required for FDA submission,
obtain FDA clearance or approval, maintain CE Marking, cost effectively
manufacture and generate revenues from the APPY1 Test at a profitable price
point, execute agreements required to successfully advance the company's
objectives, retain the management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, obtain
and enforce intellectual property rights, and realize value of intangible
assets. Furthermore, Venaxis does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter
ended June 30, 2013.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD

jdrumm@tiberend.com; (212) 375-2664

Claire Sojda
csojda@tiberend.com; (212) 375-2686

SOURCE Venaxis, Inc.

Website: http://www.venaxis.com
 
Press spacebar to pause and continue. Press esc to stop.